Natera, Inc. (NASDAQ:NTRA) Given Average Rating of "Buy" by Brokerages

Key Points

• Natera, Inc. has received an average rating of "Buy" from 19 research firms, with a consensus 12-month price target of $192.88.
• Insider selling was reported, with CEO Steven Leonard Chapman selling 5,079 shares, indicating a 3.10% decrease in his position.
• Natera reported a revenue increase of 32.2% year-over-year, with a quarterly revenue of $546.60 million, despite missing EPS estimates.

Natera, Inc. (NASDAQ:NTRA - Get Free Report) has been given an average rating of "Buy" by the nineteen research firms that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $192.8824.

A number of research firms recently weighed in on NTRA. Piper Sandler restated an "overweight" rating and issued a $220.00 price target (up previously from $210.00) on shares of Natera in a report on Monday, August 11th. Morgan Stanley restated an "overweight" rating and issued a $195.00 price target on shares of Natera in a report on Sunday, August 10th. Stephens restated an "overweight" rating and issued a $183.00 price target on shares of Natera in a report on Friday, August 15th. Wells Fargo & Company began coverage on Natera in a report on Monday, September 22nd. They issued an "equal weight" rating and a $175.00 price target on the stock. Finally, Cowen restated a "buy" rating on shares of Natera in a report on Friday, August 8th.

Insiders Place Their Bets

In other Natera news, insider John Fesko sold 678 shares of the stock in a transaction on Thursday, August 14th. The stock was sold at an average price of $155.46, for a total transaction of $105,401.88. Following the sale, the insider owned 152,747 shares in the company, valued at approximately $23,746,048.62. This represents a 0.44% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Steven Leonard Chapman sold 5,079 shares of the stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $166.53, for a total value of $845,805.87. Following the sale, the chief executive officer owned 158,514 shares in the company, valued at approximately $26,397,336.42. This trade represents a 3.10% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 43,781 shares of company stock worth $6,350,095. 5.63% of the stock is owned by insiders.

Institutional Investors Weigh In On Natera

A number of large investors have recently bought and sold shares of NTRA. Mackenzie Financial Corp grew its holdings in Natera by 33.9% during the 4th quarter. Mackenzie Financial Corp now owns 4,317 shares of the medical research company's stock valued at $683,000 after buying an additional 1,092 shares during the last quarter. Wealth Enhancement Advisory Services LLC lifted its stake in shares of Natera by 79.5% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 19,493 shares of the medical research company's stock worth $3,086,000 after purchasing an additional 8,635 shares during the period. GAMMA Investing LLC lifted its stake in shares of Natera by 18,607.6% during the 1st quarter. GAMMA Investing LLC now owns 119,916 shares of the medical research company's stock worth $16,957,000 after purchasing an additional 119,275 shares during the period. Rhumbline Advisers lifted its stake in shares of Natera by 10.9% during the 1st quarter. Rhumbline Advisers now owns 153,402 shares of the medical research company's stock worth $21,693,000 after purchasing an additional 15,121 shares during the period. Finally, Harbor Investment Advisory LLC lifted its stake in shares of Natera by 419.2% during the 1st quarter. Harbor Investment Advisory LLC now owns 1,677 shares of the medical research company's stock worth $237,000 after purchasing an additional 1,354 shares during the period. Institutional investors and hedge funds own 99.90% of the company's stock.

Natera Trading Up 0.1%

NASDAQ NTRA opened at $163.09 on Tuesday. The business's 50 day moving average is $159.32 and its two-hundred day moving average is $156.28. Natera has a 12-month low of $117.27 and a 12-month high of $183.00. The stock has a market capitalization of $22.38 billion, a price-to-earnings ratio of -85.39 and a beta of 1.68.

Natera (NASDAQ:NTRA - Get Free Report) last released its earnings results on Thursday, August 7th. The medical research company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.14). Natera had a negative return on equity of 22.22% and a negative net margin of 12.89%.The business had revenue of $546.60 million for the quarter, compared to analyst estimates of $476.84 million. During the same quarter in the previous year, the firm posted ($0.30) EPS. The business's revenue for the quarter was up 32.2% on a year-over-year basis. Natera has set its FY 2025 guidance at EPS. Equities analysts forecast that Natera will post -1.49 earnings per share for the current fiscal year.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.